

Rosario Pivonello

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7004413/rosario-pivonello-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

211
papers

9,700
citations

59
h-index

90
g-index

222
ext. papers

11,529
ext. citations

6.1
avg, IF

5.99
L-index

#	Paper	IF	Citations
211	Clinical Case 1 2022 , 271-279		
210	Interferenti endocrini e funzione gonadica: focus su steroidogenesi testicolare e infertilità maschile. <i>L Endocrinologo</i> , 2022 , 23, 52	0	0
209	Long-term high-dose L-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	1
208	Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity.. <i>Scientific Reports</i> , 2022 , 12, 4368	4.9	1
207	The dopaminergic control of Cushing's syndrome.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	0
206	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma.. <i>Frontiers in Oncology</i> , 2022 , 12, 874091	5.3	1
205	Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence [Authors' reply]. <i>Lancet Diabetes and Endocrinology</i> , 2022 , 10, 385-387	18.1	0
204	Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 791633	5.7	
203	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 847-875	18.1	48
202	Subclinical male hypogonadism. <i>Minerva Endocrinology</i> , 2021 , 46, 252-261	2.5	2
201	A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. <i>Frontiers in Endocrinology</i> , 2021 , 12, 747549	5.7	3
200	Risk Factors Affecting Puberty: Environment, Obesity, and Lifestyles. <i>Trends in Andrology and Sexual Medicine</i> , 2021 , 171-200	0.5	
199	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. <i>Neuroendocrinology</i> , 2021 , 111, 1066-1085	5.6	31
198	Sperm Global DNA Methylation (SGDM) in Semen of Healthy Dogs. <i>Veterinary Sciences</i> , 2021 , 8,	2.4	1
197	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 595894	5.7	4
196	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 2845-2847	5.2	6
195	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2021 , 16, 159-174	4.1	3

194	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <i>Pituitary</i> , 2021 , 24, 104-115	4.3	10
193	Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome. <i>Endocrine Practice</i> , 2021 , 27, 471-477	3.2	1
192	Remission in Cushing's disease is predicted by cortisol burden and its withdrawal following pituitary surgery. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 1869-1878	5.2	2
191	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 275-296	10.5	56
190	Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. <i>Frontiers in Endocrinology</i> , 2021 , 12, 662865	5.7	8
189	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. <i>Endocrine Practice</i> , 2021 , 27, 1216-1224	3.2	1
188	Hyperprolactinemia after menopause: Diagnosis and management. <i>Maturitas</i> , 2021 , 151, 36-40	5	0
187	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. <i>Obesity Reviews</i> , 2021 , e13390	10.6	3
186	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	3
185	Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 472-473	18.1	30
184	Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1613-1622	5.2	8
183	SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Societ�Italiana di Andrologia e Medicina della Sessualit�). <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1153-1157	5.2	58
182	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 654-656	18.1	13
181	Vitamin D-Induced Molecular Mechanisms to Potentiate Cancer Therapy and to Reverse Drug-Resistance in Cancer Cells. <i>Nutrients</i> , 2020 , 12,	6.7	27
180	Bisphenol A: an emerging threat to female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020 , 18, 22	5	51
179	Erectile dysfunction and cardiovascular risk: a review of current findings. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 155-164	2.5	12
178	Smoke, alcohol and drug addiction and female fertility. <i>Reproductive Biology and Endocrinology</i> , 2020 , 18, 21	5	21
177	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	13

176	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1141-1147	5.2	74
175	Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. <i>European Journal of Endocrinology</i> , 2020 , 182, 207-217	6.5	14
174	Osteoporosis: May Doping Cause It?. <i>Trends in Andrology and Sexual Medicine</i> , 2020 , 163-173	0.5	
173	ACTH increment post total bilateral adrenalectomy for Cushing's disease: a consistent biosignature for predicting Nelson's syndrome. <i>Pituitary</i> , 2020 , 23, 488-497	4.3	7
172	Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study. <i>Pituitary</i> , 2020 , 23, 203-211	4.3	11
171	Male and female sexual dysfunction in diabetic subjects: Focus on new antihyperglycemic drugs. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 21, 57-65	10.5	8
170	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020 , 1	10.5	14
169	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020 , 11, 648	5.7	23
168	Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 748-761	18.1	47
167	The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 57-73	5.2	8
166	Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 99	4.2	6
165	People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1391-1408	5.2	24
164	Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. <i>Scientific Reports</i> , 2019 , 9, 11695	4.9	9
163	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 855-865	18.1	34
162	Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico-Andrologo survey. <i>Andrology</i> , 2019 , 7, 769-777	4.2	24
161	Acromegaly. <i>Nature Reviews Disease Primers</i> , 2019 , 5, 20	51.1	128
160	Dopamine Agonists: From the 1970s to Today. <i>Neuroendocrinology</i> , 2019 , 109, 34-41	5.6	6
159	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence". <i>Endocrine</i> , 2019 , 64, 657-672	4	20

158	Advances in the medical treatment of Cushing's syndrome. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 300-312	18.1	58
157	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. <i>World Neurosurgery</i> , 2019 , 127, 695-709	2.1	9
156	Acromegaly and Heart Failure. <i>Heart Failure Clinics</i> , 2019 , 15, 399-408	3.3	11
155	OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3). <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	3
154	SUN-463 Tumor Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushing Disease Due to Pituitary Macroadenomas. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	2
153	Long-Term Complications of Hypercortisolism 2019 , 341-359		1
152	SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM). <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	1
151	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018 , 325-374	0.1	
150	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018 , 61, 118-124	4	13
149	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018 , 1-50	0.1	
148	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 17-26	18.1	75
147	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. <i>Endocrine</i> , 2018 , 62, 663-680	4	7
146	Recombinant FSH Improves Sperm DNA Damage in Male Infertility: A Phase II Clinical Trial. <i>Frontiers in Endocrinology</i> , 2018 , 9, 383	5.7	17
145	ACTH-Secreting Pituitary Tumors 2018 , 248-260		
144	Smoke, alcohol and drug addiction and male fertility. <i>Reproductive Biology and Endocrinology</i> , 2018 , 16, 3	5	79
143	Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. <i>Endocrine</i> , 2018 , 60, 65-72	4	4
142	Air pollution and female fertility: a systematic review of literature. <i>Reproductive Biology and Endocrinology</i> , 2018 , 16, 117	5	60
141	The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome. <i>Endocrine</i> , 2017 , 55, 564-572	4	24

140	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine</i> , 2017 , 55, 872-884	4	28
139	Cushing's disease: the burden of illness. <i>Endocrine</i> , 2017 , 56, 10-18	4	107
138	Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 273-283	10.5	53
137	Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. <i>Pituitary</i> , 2017 , 20, 46-62	4.3	116
136	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 577-589	5.2	39
135	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , 2017 , 158, 1527-1532	4.8	10
134	Cardiovascular alterations in adult GH deficiency. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017 , 31, 25-34	6.5	24
133	Association between vitamin D and sperm parameters: Clinical evidence. <i>Endocrine</i> , 2017 , 58, 194-198	4	24
132	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. <i>Endocrine</i> , 2017 , 57, 539-543	4	6
131	Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 661-671	5.6	16
130	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017 , 24, 495-504	5.7	41
129	The environment and male reproduction: The effect of cadmium exposure on reproductive function and its implication in fertility. <i>Reproductive Toxicology</i> , 2017 , 73, 105-127	3.4	119
128	The role of vitamin D in male fertility: A focus on the testis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017 , 18, 285-305	10.5	41
127	Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. <i>Endocrine</i> , 2017 , 56, 603-620	4	10
126	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. <i>Endocrine</i> , 2017 , 57, 314-325	4	14
125	Six controversial issues on subclinical Cushing's syndrome. <i>Endocrine</i> , 2017 , 56, 262-266	4	29
124	Cardiovascular risk after cessation of growth hormone treatment in people born small for gestational age. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 930-932	18.1	0
123	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0186508	3.7	21

122	Is mortality in Cushing's disease reversible with remission?. <i>Lancet Diabetes and Endocrinology, the</i> , 2016 , 4, 551-2	18.1	2
121	Osilodrostat, a potent oral 11 β hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. <i>Pituitary</i> , 2016 , 19, 138-48	4.3	87
120	The effect of FT500 Plus(□) on ovarian stimulation in PCOS women. <i>Reproductive Toxicology</i> , 2016 , 59, 40-4	3.4	12
119	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. <i>Bone</i> , 2016 , 86, 79-85	4.7	17
118	The safety of treatments for prolactinomas. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 503-12	4.1	16
117	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 9718-31	3.3	18
116	Influence of Bisphenol A on Type 2 Diabetes Mellitus. <i>International Journal of Environmental Research and Public Health</i> , 2016 , 13,	4.6	50
115	Investigation of sperm telomere length as a potential marker of paternal genome integrity and semen quality. <i>Reproductive BioMedicine Online</i> , 2016 , 33, 404-11	4	40
114	Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study. <i>Endocrine</i> , 2016 , 54, 516-523	4	19
113	Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. <i>Frontiers of Hormone Research</i> , 2016 , 46, 54-65	3.5	22
112	Comment on Azmahani et al. "Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions". <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016 , 155, 177	5.1	
111	Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes and Endocrinology, the</i> , 2016 , 4, 611-29	18.1	229
110	Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. <i>Pituitary</i> , 2015 , 18, 604-12	4.3	39
109	The Treatment of Cushing's Disease. <i>Endocrine Reviews</i> , 2015 , 36, 385-486	27.2	262
108	Adverse events associated with somatostatin analogs in acromegaly. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1213-26	4.1	25
107	The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. <i>Endocrine</i> , 2015 , 50, 725-40	4	36
106	The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. <i>Journal of Hypertension</i> , 2015 , 33, 44-60	1.9	92
105	Erectile Dysfunction is Common among Men with Acromegaly and is Associated with Morbidities Related to the Disease. <i>Journal of Sexual Medicine</i> , 2015 , 12, 1184-93	1.1	16

104	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. <i>Orphanet Journal of Rare Diseases</i> , 2015 , 10, 91	4.2	15
103	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015 , 9, 129	5.1	86
102	Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. <i>Journal of Endocrinological Investigation</i> , 2014 , 37, 99-112	5.2	24
101	LCI699, a potent 11 β hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 1375-83	5.6	135
100	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. <i>Osteoporosis International</i> , 2014 , 25, 441-6	5.3	38
99	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. <i>Gene</i> , 2014 , 534, 282-5	3.8	22
98	Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. <i>Clinical Endocrinology</i> , 2014 , 81, 408-17	3.4	78
97	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014 , 21, 601-13	5.7	22
96	Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. <i>European Journal of Endocrinology</i> , 2014 , 170, 311-9	6.5	45
95	Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. <i>Journal of Endocrinological Investigation</i> , 2014 , 37, 1017-30	5.2	34
94	Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). <i>European Journal of Endocrinology</i> , 2014 , 171, 263-73	6.5	27
93	Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type 1a and with granulocyte colony-stimulating factor therapy in type 1b. <i>Hormone Research in Paediatrics</i> , 2014 , 81, 55-62	3.3	14
92	How should patients with adrenal incidentalomas be followed up?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 352-4	18.1	1
91	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2014 , 46, 181-98	4	27
90	Cushing, acromegaly, GH deficiency and tendons. <i>Muscles, Ligaments and Tendons Journal</i> , 2014 , 4, 329-329		8
89	Investigational therapies for acromegaly. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 955-63	5.9	12
88	Preoperative workup in the assessment of adrenal incidentalomas: outcome from 282 consecutive laparoscopic adrenalectomies. <i>BMC Surgery</i> , 2013 , 13, 57	2.3	26
87	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 557-567	1.1	2

86	The metabolic profile in active acromegaly is gender-specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E51-9	5.6	38
85	Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 372-9	5.6	70
84	Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. <i>European Journal of Endocrinology</i> , 2013 , 168, 15-22	6.5	23
83	Endocrine changes (beyond diabetes) after bariatric surgery in adult life. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 267-79	5.2	4
82	Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. <i>Pituitary</i> , 2012 , 15, 539-51	4.3	26
81	Growth hormone, prolactin, and sexuality. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 782-94	5.2	47
80	Subclinical Cushing's syndrome. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012 , 26, 497-505	6.5	47
79	Predictors of morbidity and mortality in acromegaly: an Italian survey. <i>European Journal of Endocrinology</i> , 2012 , 167, 189-98	6.5	144
78	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. <i>Clinical Endocrinology</i> , 2012 , 76, 264-71	3.4	51
77	Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 154-9	5.2	11
76	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. <i>European Journal of Endocrinology</i> , 2011 , 165, 713-21	6.5	57
75	Resistance to somatostatin analogs in acromegaly. <i>Endocrine Reviews</i> , 2011 , 32, 247-71	27.2	186
74	Pathophysiology of diabetes mellitus in Cushing's syndrome. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 77-83	3.6	116
73	The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 663-70	5.2	29
72	Cardiovascular disease in Cushing's syndrome: heart versus vasculature. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 50-4	5.6	74
71	Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. <i>Progress in Brain Research</i> , 2010 , 182, 281-94	2.9	24
70	Medical Treatment of Cushing's Disease with Pasireotide. <i>European Endocrinology</i> , 2010 , 8, 99	3.4	4
69	Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2907-14	5.6	41

68	Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 528-37	5.6	47
67	Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3746-56	5.6	107
66	Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009 , 71, 237-45	3.4	51
65	Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 2009 , 32, 390-4	5.2	19
64	The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 223-30	5.6	250
63	Cushing's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 135-49, ix	5.5	132
62	Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. <i>European Journal of Endocrinology</i> , 2008 , 158, 623-30	6.5	160
61	Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 2639-46	5.6	64
60	Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1412-7	5.6	96
59	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008 , 23, 1331-1331		
58	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 497-506	5.2	13
57	Cushing's syndrome: aftermath of the cure. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007 , 51, 1381-91		59
56	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S13-S21	6.5	90
55	Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. <i>European Journal of Endocrinology</i> , 2007 , 157, 359-66	6.5	51
54	Dopamine receptor expression and function in corticotroph ectopic tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 65-9	5.6	58
53	Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 476-82	5.6	59
52	Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2007 , 157, 579-87	6.5	65
51	Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 1779-84	5.6	90

50	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. <i>European Journal of Endocrinology</i> , 2006 , 154, 467-77	6.5	133
49	The metabolic syndrome and cardiovascular risk in Cushing's syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005 , 34, 327-39, viii	5.5	117
48	Cabergoline plus lanreotide for ectopic Cushing's syndrome. <i>New England Journal of Medicine</i> , 2005 , 352, 2457-8	59.2	68
47	Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6616-22	5.6	29
46	Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4493-502	5.6	63
45	Dopamine receptor expression and function in corticotroph pituitary tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2452-62	5.6	210
44	Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 1674-83	5.6	97
43	Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004 , 3, 309-18		26
42	Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2076-80	5.6	69
41	Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1629-36	5.6	82
40	Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2527-33	5.6	264
39	Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. <i>Clinical Endocrinology</i> , 2003 , 58, 169-76	3.4	87
38	Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. <i>Clinical Endocrinology</i> , 2003 , 58, 302-8	3.4	82
37	High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3196-201	5.6	98
36	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. <i>European Journal of Endocrinology</i> , 2003 , 148, 325-31	6.5	158
35	Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2003 , 26, 82-8	5.2	15
34	Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. <i>Clinical Endocrinology</i> , 2002 , 56, 153-8	3.4	62
33	Dopamine receptor agonists for treating prolactinomas. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 787-800	5.9	90

32	Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 4193-7	5.6	32
31	Early vascular alterations in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3174-8	5.6	91
30	The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1088-93	5.6	86
29	Cardiovascular consequences of early-onset growth hormone excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3097-104	5.6	74
28	Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. <i>Journal of Endocrinological Investigation</i> , 2002 , 25, 932-7	5.2	5
27	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , 2001 , 54, 97-106	3.4	6
26	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001 , 54, 515-24	3.4	84
25	Cardiovascular complications in acromegaly: methods of assessment. <i>Pituitary</i> , 2001 , 4, 251-7	4.3	22
24	Spine abnormalities and damage in patients cured from Cushing's disease. <i>Pituitary</i> , 2001 , 4, 153-61	4.3	28
23	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. <i>Pituitary</i> , 2001 , 4, 187-93	4.3	1
22	Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 5256-61	5.6	169
21	Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1551-7	5.6	94
20	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. <i>Clinical Endocrinology</i> , 2000 , 52, 319-27	3.4	76
19	Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study. <i>Clinical Endocrinology</i> , 2000 , 52, 447-55	3.4	28
18	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. <i>Clinical Endocrinology</i> , 2000 , 53, 53-60	3.4	60
17	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000 , 53, 13-9	3.4	43
16	Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 2247-52	5.6	146
15	Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1919-24	5.6	138

14	Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2664-72	5.6	291
13	Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2349-52	5.6	9
12	The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1277-82	5.6	80
11	Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1986-91	5.6	58
10	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999 , 1, 115-20	4.3	69
9	Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. <i>Journal of Endocrinological Investigation</i> , 1999 , 22, 860-5	5.2	50
8	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 1998 , 49, 77-84	3.4	12
7	Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. <i>Clinical Endocrinology</i> , 1998 , 48, 655-62	3.4	56
6	Impairment of bone status in patients with central diabetes insipidus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2275-80	5.6	21
5	Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3574-9	5.6	127
4	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects		22
3	Effect of a Short-Term Treatment with Alendronate on Bone Density and Bone Markers in Patients with Central Diabetes Insipidus		5
2	Early Vascular Alterations in Acromegaly		19
1	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine Abstracts</i> ,		2